Loading clinical trials...

COMPLETEDNA

Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition

A Randomized, Evaluator-blinded, Parallel Group, no Treatment Controlled, Multicenter Study to Evaluate Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition

NCT05622812•Galderma R&D

View on ClinicalTrials.gov

Summary

This study is designed to evaluate effectiveness and safety of Restylane Lyft Lidocaine for Jawline definition

Detailed Description

A randomized, evaluator-blinded, parallel group, no treatment controlled, multicenter study to evaluate effectiveness and safety of Restylane Lyft Lidocaine for Jawline definition in Canada

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Male and female adults willing to comply with the requirements of the study and providing a signed written informed consent
•Consent the use of facial images for marketing purposes and educational material
•Subject with moderate to very severe (Grade 2 to 4) on the GJS
•Subject is willing to abstain from any other facial, submental, and/or neck aesthetic procedure(s) or implant
•Female of childbearing potential with a negative urine pregnancy test before treatment

Exclusion Criteria

•Subjects presenting with known/previous allergy or hypersensitivity to hyaluronic acid (HA) filler, lidocaine or other amide-type local anesthetics
•Subjects presenting with known/previous allergy or hypersensitivity to streptococcal proteins
•Subject with bleeding disorders or taking thrombolytics or anticoagulants
•Prior surgical procedure in the treatment area
•History of other facial treatment/procedure in the previous 6 months HA in or near the intended treatment site
•Presence of any disease or lesions near or on the area to be treated
•Presence of any condition, in the opinion of the Treating Investigator, makes the subject unable to complete the study per protocol
•Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period
•Study site personnel, close relatives of the study site personnel, employees, or close relatives of employees at the Sponsor Company
•Participation in any other interventional clinical study within 30 days before treatment

Locations (9)

Galderma Research Site

Vancouver, British Columbia, Canada

Galderma Research Site

Vancouver, British Columbia, Canada

Galderma Research Site

Burlington, Ontario, Canada

Galderma Research Site

London, Ontario, Canada

Galderma Research Site

Oakville, Ontario, Canada

Galderma Research Site

Toronto, Ontario, Canada

Galderma Research Site

Windsor, Ontario, Canada

Galderma Research Site

Woodbridge, Ontario, Canada

Galderma Research Site

Westmount, Quebec, Canada

Key Dates

Start Date

February 16, 2023

Primary Completion Date

October 16, 2023

Completion Date

June 14, 2024

Last Updated

March 7, 2025

Enrollment

140

ACTUAL participants

Conditions

Jawline Definition

Interventions

Restylane Lyft Lidocaine

DEVICE

Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition

NCT03712137

Jawline Definition

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions